American Renal Associates Holdings Inc. (NYSE:ARA) fell 2% during trading on Wednesday . The stock traded as low as $24.78 and last traded at $25.19, with a volume of 294,980 shares changing hands. The stock had previously closed at $25.71.

Several research firms recently commented on ARA. SunTrust Banks Inc. began coverage on American Renal Associates Holdings in a report on Monday, May 16th. They issued a “buy” rating and a $34.00 price target for the company. Wells Fargo & Co. began coverage on American Renal Associates Holdings in a report on Monday, May 16th. They issued an “outperform” rating for the company. Leerink Swann reaffirmed an “outperform” rating on shares of American Renal Associates Holdings in a report on Monday, May 16th. Goldman Sachs Group Inc. began coverage on American Renal Associates Holdings in a report on Monday, May 16th. They issued a “neutral” rating and a $30.00 price target for the company. Finally, Barclays PLC began coverage on American Renal Associates Holdings in a report on Monday, May 16th. They issued an “overweight” rating and a $33.00 price target for the company. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $32.50.

The stock has a 50 day moving average of $0.00 and a 200-day moving average of $0.00. The firm has a market capitalization of $566.58 million and a P/E ratio of 12.99.

American Renal Associates Holdings (NYSE:ARA) last issued its quarterly earnings results on Thursday, May 12th. The company reported $0.16 earnings per share for the quarter. The business earned $172.10 million during the quarter, compared to analyst estimates of $149.30 million. Equities analysts expect that American Renal Associates Holdings Inc. will post $0.88 EPS for the current year.

American Renal Associates Holdings, Inc is a dialysis services provider in the United States. The Company focuses on joint venture partnerships with physicians. The Company’s segment is the ownership and operation of dialysis clinics. It provides patient care and clinical outcomes to patients suffering from the advanced stage of chronic kidney disease, known as end stage renal disease (ESRD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.